Apr 5, 2024 · What Causes an Exon 20 Insertion Mutation? Getting a Diagnosis; Questions for Your Doctor; How Is an Exon 20 Insertion Mutation Treated?

Oct 1, 2024 · EGFR exon 20 insertions are one type of lung cancer biomarker. They are a type of EGFR mutation that leads to uncontrolled cell growth. Who is likely to have an EGFR exon 20 insertion mutation? Patients who test positive for an EGFR mutation may have an exon 20 insertion mutation.

Oct 21, 2023 · Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease...

The Exon 20 Group is a laser-focused, multi-stakeholder, global coalition of patients, care partners, family members, thoracic/medical oncologists, scientists, molecular profiling labs, and pharmaceutical companies and biotechs with the mission of converting exon 20 insertion mutations into chronic diseases and then curing them.

Mar 8, 2023 · Exon 20 mutations account for approximately 1 in 30 lung cancer cases and are more commonly found in nonsmoking individuals and Asian persons. Exon 20 mutations are found in a gene called epidermal growth factor receptor (EGFR), which is involved in the growth and division of cells.

Mar 13, 2023 · The EGFR exon 20 insertion mutation, or exon 20, is a rare form of non-small cell lung cancer (NSCLC) that accounts for up to approximately 1 in 30 lung cancer cases. It is more common in people who never smoked and in Asian persons.

EGFR exon 20 insertions are less responsive to conventional tyrosine kinase inhibitors (TKIs), leading to the development of targeted agents. This review explores key therapeutic agents, such as Amivantamab, Mobocertinib, Poziotinib, Zipalertinib, and Sunvozertinib, which have shown promise in treating NSCLC with EGFR exon 20 insertions.

Mar 10, 2020 · EGFR exon 20 insertions accounted for 4% of all the EGFR mutations; however, their forms and locations vary. Exon back-end insertion (a767-c775) was associated with EGFR-TKI resistance, and front-end insertion (e762-y764) …

Exon 20 of EGFR contains 2 important regions spanning across AA762–775: the regulatory αC-helix domain (AA762–766) and the adjacent loop that follows it (AA767–775) . Ex20ins mutations are heterogeneous in nature and include in-frame insertions or …

Mar 17, 2025 · Exon 20 of the EGFR gene plays a unique role in NSCLC due to insertion mutations that alter receptor function. Unlike common EGFR mutations in exons 18, 19, and 21, which increase sensitivity to tyrosine kinase inhibitors (TKIs), exon 20 insertions often confer resistance to these treatments.